Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Study of Gelonin Purging of Autologous Stem Cells for Transplantation
- Conditions
- Myelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00043810
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
- Conditions
- SclerodermaSystemic Sclerosis
- First Posted Date
- 2002-07-10
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Target Recruit Count
- 15
- Registration Number
- NCT00040651
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
- Conditions
- Sickle Cell AnemiaHemoglobinopathyThalassemia
- First Posted Date
- 2002-06-27
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT00040417
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases
- Conditions
- LeukemiaLymphoma
- Interventions
- Procedure: Megadose of CD34 Selected Progenitor CellsDrug: MelphalanDrug: ThiotepaDrug: FludarabineDrug: Rabbit ATG
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00038857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic SyndromeChronic Lymphocytic Leukemia
- Interventions
- Drug: MylotargDrug: FludarabineDrug: MelphalanDrug: Anti-thymocyte globulinProcedure: Stem cell transplant
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT00038831
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
- Conditions
- LymphomaLeukemia
- Interventions
- First Posted Date
- 2002-06-07
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00038844
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
- Conditions
- HemoglobinopathiesAnemia, Sickle CellHemoglobin SC DiseaseThalassemiaThalassemia Major
- Interventions
- First Posted Date
- 2002-05-01
- Last Posted Date
- 2013-05-01
- Target Recruit Count
- 2
- Registration Number
- NCT00034528
- Locations
- 🇺🇸
Dana-Farber Cancer Institute/Harvard Cancer Center, Brigham and Women's Hospital and Massachusetts General Hospital, Boston, Massachusetts, United States
Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders
- Conditions
- Metabolism, Inborn ErrorsGranulomatous Disease, Chronic
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00010361
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Myeloma Immunoglobulin Idiotype VaccineDrug: BortezomibDrug: CyclophosphamideBiological: GMCSF (granulocyte macrophage colony stimulating factor)Drug: CyclosporineDrug: Doxorubicin hydrochlorideDrug: EtoposideDrug: Fludarabine phosphateDrug: PrednisoneDrug: Vincristine SulfateDrug: MethotrexateBiological: GCSF (granulocyte colony stimulating factor)
- First Posted Date
- 2000-08-24
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00006184
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
- Conditions
- Fanconi's Anemia
- First Posted Date
- 2000-06-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00005898
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.